Tirzepatide

Overview

Lyochem supplies Tirzepatide as a sequence-verified analytical reference standard for incretin-pharmacology research. The molecule is a 39-residue synthetic peptide carrying a C20 fatty-diacid substituent on a lysine side chain; that lipidation governs the reversible albumin binding and the long circulating half-life that set it apart from the GLP-1 mono-agonist series. Functionally it behaves as a balanced co-agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, which is why the metabolic-research literature treats it as the reference dual-incretin entity. It is the active ingredient of approved finished drugs marketed under separate names, but the material here is characterized and labelled strictly as a research reagent — not a dosage form. Each lot is released against its own analytical packet rather than as an undifferentiated bulk fill: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity within 0.5 Da of the theoretical 4813.45 g/mol, sequence confirmation by LC-MS/MS, counter-ion content, peptide content (% net peptide), and water content by Karl Fischer. Because the deletion sequences from a 39-mer SPPS run co-elute closely and are not separable by intact mass alone, the tandem-MS b/y-ion ladder is the test that demonstrates sequence identity, and Lyochem recommends requesting it on the first lot from any new source. Bacterial endotoxin (LAL) is an on-request add-on for in vivo metabolic-model work. Fills run mg-scale for reproducible aliquoting across a study series; this is reference-grade research material, distinct from compounding-scale API supply.

Applications & buyer fit

Specifications

CAS

2023788-19-2

Molecular Formula

C225H348N48O68

Molecular Weight

4813.45 g/mol

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 120 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 5 days

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion content (acetate / TFA)
• Peptide content (% net peptide)
• Bacterial endotoxin (LAL) on request — in vivo workflows

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form and not labelled for human administration. Tirzepatide is the active ingredient of approved finished drugs under separate brand names, but the bulk active supplied here is a research reagent; buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.

Selected literature

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
2. Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
3. Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626.
4. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598.
5. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119.
6. Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205.

Frequently asked questions